Myasthenia Gravis Treatment in Ranchi

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease where the body's immune system produces antibodies that attack, block, or destroy acetylcholine receptors at the neuromuscular junction — the microscopic gap between nerve endings and muscle fibers where nerve impulses trigger muscle contraction. With fewer functioning receptors, the muscle receives a weaker signal, causing fatigueable weakness that worsens with sustained or repeated activity and improves with rest. The most common form involves antibodies against the acetylcholine receptor (AChR-Ab, 85% of cases). Some patients have antibodies against muscle-specific kinase (MuSK-Ab, 5-8%) or LRP4. About 5 percent are seronegative. MG causes weakness in voluntary muscles — most commonly the eyes (drooping eyelids, double vision), face and throat (difficulty chewing, swallowing, speaking), and limbs. The thymus gland plays a role; about 10 to 15 percent of MG patients have a thymoma (tumor of the thymus). Dr. Yuvraj Lahre at Neurovision Clinic provides expert diagnosis and management of MG.

MG treatment has two pillars: symptomatic treatment and immunosuppressive therapy. Symptomatic treatment — pyridostigmine (Mestinon) is a cholinesterase inhibitor that prevents the breakdown of acetylcholine at the neuromuscular junction, increasing the amount available to bind to remaining receptors. It provides rapid but temporary improvement in muscle strength. Immunosuppressive therapy — for long-term disease control, prednisone or other corticosteroids are the most widely used agents, usually combined with steroid-sparing immunosuppressants like azathioprine, mycophenolate mofetil, or cyclosporine to minimize steroid side effects. For moderate to severe generalized MG, newer agents like rituximab (especially for MuSK-MG) or eculizumab (for refractory AChR-MG) may be considered. Thymectomy (surgical removal of the thymus gland) is recommended for AChR-antibody positive generalized MG patients under 60, as it can reduce immunosuppressive medication requirements and increase the chance of remission. Dr. Lahre discusses all treatment options and coordinates care.

A myasthenic crisis is a life-threatening complication of MG where respiratory muscle weakness leads to respiratory failure requiring mechanical ventilation. It can be triggered by infection, surgery, certain medications, pregnancy, or emotional stress. Warning signs include: rapidly worsening weakness, difficulty speaking in full sentences (breathlessness), inability to lift the head off the pillow, difficulty swallowing (with risk of aspiration), and weak cough with inability to clear secretions. Myasthenic crisis is a neurological emergency requiring immediate hospitalization and intensive care. Treatment involves plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) to rapidly remove or neutralize the pathogenic antibodies, along with ventilatory support and aggressive treatment of the triggering infection. Dr. Lahre educates every MG patient on crisis warning signs and maintains a list of medications contraindicated in MG (including certain antibiotics, beta-blockers, magnesium-containing drugs, and muscle relaxants).

Yes. With modern treatment, the vast majority of people with MG have a normal life expectancy and good quality of life. Most achieve significant improvement or remission with appropriate immunosuppressive therapy. The key principles are: early diagnosis and treatment initiation, consistent medication adherence (MG medications must never be stopped abruptly), avoidance of known trigger medications (Dr. Lahre provides each patient with a medication alert card), prompt treatment of infections, and regular specialist follow-up. Many patients return to full-time work and active lives. Pregnancy in MG requires coordinated care with neurology and obstetrics. At Neurovision Clinic, Dr. Lahre provides comprehensive, long-term care that addresses both the medical and practical aspects of living with MG.